#Cannabis #Potcast: Sproutly Canada Inc. (CSE: $SPR.C) (OTCQB: $SRUTF) Talks Company Future in Cannabis #Beverage and Consumables Market

#Cannabis #Potcast: Sproutly Canada Inc. (CSE: $SPR.C) (OTCQB: $SRUTF) Talks Company Future in Cannabis #Beverage and Consumables Market

Delta, Kelowna, BC – June 5, 2019 Investorideas.com, a global news source covering leading sectors including cannabis and its potcast site, www.potcasts.ca release today’s special edition of Investorideas.com potcasts^CM, featuring an interview with Dr. Arup Sen, the Chief Science Officer for Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF). Dr. Sen discusses Sproutly’s recent developments and how they are approaching the Canadian cannabis beverages market expected to open up this fall.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2019/053119-CSESPR.mp3

Read this in full at https://www.investorideas.com/news/2019/cannabis-potcasts/06052SPR-SRUTF-Beverage-Consumables.asp

Sproutly’s core mission is to become the leading supplier to the cannabis beverage and consumables market. The company’s Toronto-based, ACMPR licensed facility was built to cultivate pharmaceutical grade cannabis to supply a technological breakthrough in producing and formulating the first natural, truly water-soluble cannabis solution. Their water-soluble ingredients and bio-natural oils will deliver revolutionary brands to international markets that are clamouring for well-defined commercial products, and Sproutly’s business focus is to execute on partnerships with local and globally established consumer brands to leverage their existing customer bases, further expand brand loyalty, assist with marketing, and support distribution networks to deliver this scientific breakthrough with speed and efficiency worldwide.

When asked about recent developments Dr. Sen discussed Sproutly and OCC Holdings Ltd., an affiliate of Moosehead Breweries Limited’s recent announcement that they have entered into a definitive agreement to form an exclusive joint venture to develop, produce, and market non‐alcoholic cannabis-infused beverages in Canada using Sproutly’s proprietary, naturally produced water-soluble cannabinoids known as ‘Infuz₂O’.

“We will be pretty much standing alone in the field of making beverages that will include natural chemicals in their natural state from cannabis and hemp plants,” commented Dr. Sen with regards to Sproutly’s unique product capabilities.

When asked about what the Company has been doing to prepare for the recreational beverage market coming this fall, Dr. Sen talked about Sproutly’s recent stability tests for  their current formulations and the success they’ve seen so far.

“We have created about 44 different formulations, many of which have already gone through the stability testing, both in cans as well as bottles, because at this point we don’t know how the regulations will turn out. We would prefer glass bottles, because of the clear solution nature of our beverages which will stand out in a glass bottle.”

“In the stability study for glass bottles we have exceeded 5 and a half months, and in cans we are right around 4 months and a week. As you know, beer and other beverages go through a 3 to 6 month stability test and we’ve already exceeded the 3 month mark and we have not seen any change in the experience or quality,” Dr. Sen concluded.

Sproutly also recently released its premium cannabis brand for the recreational market, CALIBER. CALIBER is designed for the cannabis connoisseur and delivered via Sproutly’s craft cannabis flower production. When asked about this, as well as future Sproutly recreational products, Dr. Sen described some of the possibilities with the Company’s Bio-Natural Oils and how this separates Sproutly from its competitors.

“The next in line for us would be tinctures and capsules, which our Bio-Natural Oil perfectly fits in to. The tinctures and capsules will have their own unique features and characteristics, as our Bio-Natural Oil behaves very differently from other isolates and distillates, as ours is actually full plant oil. We could sell each by itself, or we can create blends and profiles of unique recreational value which others wouldn’t think they would be able to, because they are still stuck on Indica, Sativa and Hybrid. We, on the other hand, are focused on the unique strains, as each delivers a unique experience. We are in a position to either provide what would be considered single flower, much like a varietal of wine, and unique blends, knowing what the specific qualities of each strain are, to provide something none of the other capsules or oils will be able to provide.”

Dr. Sen also went on to discuss, in more detail, what consumers might be able to expect for product offerings with regards to their partnership with MooseHead as well as the far off future of potential IV use with their water-soluble solutions, though even Dr. Sen would be the first to say that the industry is still looking way down the road for that distant goal.

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI. 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

Disclosure:  This article/interview featuring Sproutly Canada Inc. is a paid for service on Investorideas.com ( two thousand ) . More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Follow us on Social Media

https://www.facebook.com/Investorideaspotcasts/

https://twitter.com/MJInvestorIdeas

https://www.instagram.com/potcasts_investorideas/

Contact Investorideas.com

800-665-0411

#BiotechStocks: Consumers Reaching for OTC Pain Relief over Opioids (OTCQB: $INNV) (NYSE: $PFNX) (NASDAQ: $HRTX) (OTC: $NPHC)

#BiotechStocks: Consumers Reaching for OTC Pain Relief over Opioids (OTCQB: $INNV) (NYSE: $PFNX) (NASDAQ: $HRTX) (OTC: $NPHC)

Point Roberts WA, Delta BC – June 5, 2019 - Investorideas.com, a leading investor news resource covering biotechnology and pharmaceutical stocks releases a sector snapshot reporting on the continued growth in OTC analgesics as consumers look for more affordable and effective options for pain.

In a recent report from Digital Journal “The global  OTC analgesics market is projected to register an above-average CAGR during 2017 to 2022. Global sales of OTC analgesics is estimated to account for nearly US$ 25,000 Million in revenues by 2022-end.”

“The trend of using off-label drugs that are affordable and unapproved, but effective in treating diseases, has been witnessing an upsurge over the past few years. Various off-label drugs including tricyclic antidepressants, antihistamines, anticonvulsants, selective serotonin reuptake inhibitors, anti-anxiety drugs, and steroids are being increasingly utilized for managing symptoms of pain. Symptom management associated with pain has now become convenient and easy, owing to widely available OTC analgesics, which are prescribed with approved drugs, implied as maintenance therapies. High potential has been observed for the market growth of OTC analgesics around the world, wherein demand as well as sales of pain medication including pain relievers, and pain killers, are gaining higher popularity among consumers.”

“In addition, demand for the non-narcotic pain medications has been rising significantly, owing to ill effects of consuming narcotic drugs. These factors are expected to influence growth of the global market for OTC analgesics in the upcoming years. Topical analgesic distributors as well as manufacturers are concentrating on enhancing their product portfolio, with an aim to benefit from potential growth opportunities in developing as well as developed markets. The aforementioned factors will augment the growth of global OTC analgesics market. Usually, OTC analgesic drugs are bought in large quantities, as these drugs are used for relieving different types of pain. Emergence of healthcare reforms, coupled with favorable regulatory norms across the globe, have been encouraging the uptake and initiations of various pain management programs, with an aim to lower the entire healthcare costs. These instances are estimated to pave the way for the development of effective OTC analgesics,” the report continued.

Read more: http://www.digitaljournal.com/pr/4329549#ixzz5pbu7mA3v

Innovus Pharmaceuticals, Inc. (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, just announced that it has entered into a supply relationship with a third party to supply Innovus Pharma with Omeprazole 20mg tablets and Omeprazole 20mg 24 hours delayed release capsules indicated for the treatment of frequent heartburn under the approved abbreviated new drug application (“ANDA”) No. 207891 from the US Food and Drug Administration.  Innovus Pharma will launch the drug under its own trademark OmepraCare™ 20mg tablets and OmepraCare™ DR 20mg 24 hours delayed release capsules.

Read this in full at https://www.investorideas.com/news/2019/biotech/06051Stocks-OTCPainRelief.asp

“We continue to execute on our plan to launch new OTC drugs in niche therapeutic areas where there is a need for national brands to leverage our success with FlutiCare® and other drugs and devices we have in the United States.  OmepraCare DR™ is the third ANDA OTC drug that we intent to commercialize in the US this year,” said Dr. Bassam Damaj, Innovus Pharma’s President and Chief Executive Officer.  “We believe that the market opportunity for us with this product is fairly large given the success of the product Prilosec® OTC and the relatively large size of the market. Our goal is to launch OmepraCare™ in the US in the second half of this year,” added Dr. Damaj.

“In addition, it is our current intention to add up to 10 additional ANDA OTC products to our US drug pipeline,” he continued.

This follows Innovus announcement of receiving the CPNP notification number required to commercialize Diabasens® in all 28 member countries of the European Union. This represents the fourth Innovus Pharma product to receive CPNP notification in the European Union in the last few years, the others being for Zestra®, Zestra Glide® and Sensum+®. The product will be available as an over-the-counter (“OTC”) or behind the counter product and does not require a prescription.

“We are pleased to announce the receipt of the CPNP in the European Union for Diabasens®, our current best-selling product. The clearance to market the product in Europe follows the recently announced approval from Health Canada for the relief of neuropathy pain,” said Dr. Bassam Damaj. “This is one of several products we have filed in Europe for which we expect to receive the notification to commercialize in the near future.”

Pfenex Inc. (NYSE: PFNX) and Alvogen also expressed their interest in the EU, as they announced that the European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) submitted by their partner Alvogen for PF708 (teriparatide).  The product is proposed as a therapeutic equivalent in the treatment of osteoporosis to Forteo®and is filed with the EMA as a biosimilar in the treatment of osteoporosis to Forsteo®, which achieved $289 million sales in the EU and $1.6 billion in global product sales in 2018. This acceptance means the EMA considers the MAA to be complete and initiates the EMA's formal review process.

“The acceptance of the PF708 MAA filing is an important milestone for Pfenex and Alvogen and demonstrates that through our collaborative partnership, we continue making progress towards potential approvals beyond the United States,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex. “Subject to applicable regulatory approvals for Europe, PF708 will be commercialized by Theramex, a leading global specialty pharmaceutical company dedicated to Women’s Health.”

“We are very pleased with the EMA’s acceptance of the MAA for review. This is an important milestone and underlines the successful and valuable partnership between Pfenex and Alvogen to bring biosimilar Teriparatide to market and deliver on our mission to provide high quality, affordable healthcare for patients. The EMA will review the application under the centralized marketing authorization procedure. If approved by the EMA, biosimilar Teriparatide would receive marketing authorization in all 28 member states of the European Union (EU), as well as in Iceland, Liechtenstein and Norway,” stated Faysal Kalmoua, Executive Vice President of Alvogen’s Global Portfolio.

Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, recently announced that the results from the pivotal Phase 3 EPOCH 1 bunionectomy study of the investigational agent HTX-011 have been published online by the Regional Anesthesia & Pain Medicine (RAPM) journal. The article, entitled "HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in bunionectomy: phase III results from the randomized EPOCH 1 study," will also be published in the July 2019 print issue of RAPM. HTX-011 achieved all primary and key secondary endpoints in the EPOCH 1 study, demonstrating statistically significant reductions in both pain intensity and the use of opioid rescue medications following surgery and an increase in the proportion of patients who were opioid-free.

HTX-011 is a dual-acting, fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug Meloxicam in a 33:1 ratio. It is the first and only extended-release local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and opioid use through 72 hours compared to bupivacaine solution, the current standard-of-care local anesthetic for postoperative pain control.

In the EPOCH 1 study, all primary and key secondary endpoints were achieved. HTX-011 provided superior and sustained pain reduction compared to placebo and bupivacaine solution through the critical 72-hour postoperative window, when pain is often most severe. Significant reductions in pain occurred both early (in the first 8 through 24 hours) and were sustained from 24 through 72 hours. In addition to reductions in average pain intensity scores, HTX-011 significantly reduced the proportion of patients experiencing severe pain through 72 hours compared to placebo and bupivacaine solution. Significant reductions in pain were consistent with the significant decrease in total opioid consumption and the significant increase in opioid-free patients receiving HTX-011, both through 72 hours and as compared to placebo and bupivacaine solution. Most patients that required no opioids in the first 72 hours after surgery (82%) continued to be opioid-free through 28 days. HTX-011 was well tolerated, with a safety profile comparable to placebo and bupivacaine solution.

"This publication demonstrates that HTX-011 can significantly reduce postoperative pain, including severe pain, for 72 hours post-surgery and reduce the need for opioids compared to bupivacaine solution," said Eugene Viscusi, MD, Professor of Anesthesiology and Chief of Pain Medicine in the Department of Anesthesiology at the Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia, Pennsylvania. "Surgery can contribute to the opioid problem, as it is often a patient's initial introduction to opioids, and it also can be the trigger for misuse and abuse due to unused pills from discharge prescriptions. Each year, an estimated 2.6 million Americans may become persistent opioid users following initial opioid exposure after surgery. The results from EPOCH 1 suggest that HTX-011 can be used to control pain effectively after surgery, thereby reducing the reliance on opioids and preventing the flow of unused opioid pills into our homes and communities."

Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, recently announced that the iRemedy Healthcare Companies has added the entire Nyloxin product line to their marketplace.

“We are pleased to be working with iRemedy to expand the marketing of Nyloxin,” explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We have only recently brought the Nyloxin product line back under our control and updated both the Nyloxin website and the Nutra Pharma corporate website. These efforts to increase internet awareness will continue as we join other marketing groups to greatly expand our reach to educate consumers about Nyloxin and get the product into the hands of those who need it most,” he continued. “We will also be working with iRemedy to increase the visibility of Nyloxin in the medical space in an effort to educate healthcare professionals about the power of Nyloxin as an analgesic of choice,” he concluded.

By adding Nyloxin to the iRemedy vendor network, Nutra Pharma will have the ability to process orders, access sales channels, gain promotion online with paid ads and social media, and work with thousands of independent medical representatives targeting medical practices, hospitals and other healthcare providers. The iRemedy vendor program includes infrastructure services like online promotions, order capture, order fulfillment, and can be extended to include marketing and sales team development.

“This marketplace e-commerce approach, one that is built on quality control and compliance, is revolutionizing healthcare by providing market access to emerging device, drug and supply companies. Just as Amazon, Netflix and iTunes revolutionized their markets by creating efficient and accessible distribution communities, iRemedy is bringing marketplace efficiency to the US healthcare market,” stated Tony Paquin, CEO of iRemedy. “We’re excited to be working with Nutra Pharma and we know that providing people alternatives to narcotics-based pain relief medication is necessary for good communal health. That’s why we love this product and we’re glad to have it as part of the iRemedy family,” he concluded.  

Nyloxin® is a safe, non-narcotic, and non-addictive homeopathic pain reliever for the relief of pain without impairing cognitive function. Nyloxin® offers several benefits as pain relievers and anti-inflammatory agents. Nyloxin® has a well-defined safety profile. Since the early 1930s, the active pharmaceutical ingredient (API), Asian cobra venom, has been studied in more than 46 human clinical studies.

Another report from Future Market Insights also focused on the increased use of OTC pain medications saying, “The OTC (over-the-counter) pain medication market surpassed US$ 18 billion in 2018, with growth influenced by changing perceptions on generic pharmaceutical drugs, according to a recent study published by Future Market Insights (FMI). The study opines that market revenue will rev up at an improved rate of 3.7% to exceed US$ 19.3 billion in 2019.”

“As more consumers make the shift to generic drugs to reduce total spending on non-prescription or OTC pain medication, various governing bodies, such as the United States Food and Drug Administration (FDA), have implemented stringent regulations and labeling rules to ensure the safety and effectiveness of OTC pain medications. This is allowing for leading companies in the OTC pain medication market to collaborate with generic drug-makers to capitalize on the trend of consumer inclination towards generic versions of branded OTC pain medications”, finds FMI.

About Investorideas.com - News that Inspires Big Investing Ideas

https://www.investorideas.com/About/

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: this  article featuring INNV is a paid for service on Investorideas.com ( two thousand ) by a third party. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Contact Investorideas.com

800-665-0411

#Technology and the #Automotive Sector–Connected Cars Driving the Future of Vehicle Safety (TSXV: $SIM.V) (OTCQX: $SYATF) (NYSE: $BB) (NASDAQ: $TSLA) (TSX: $T.TO)

#Technology and the #Automotive Sector–Connected Cars Driving the Future of Vehicle Safety (TSXV: $SIM.V) (OTCQX: $SYATF) (NYSE: $BB) (NASDAQ: $TSLA) (TSX: $T.TO)

Point Roberts WA, Delta BC – June 5, 2019 - Investorideas.com, a leading investor news resource covering technology and automotive stocks releases a sector snapshot reporting on connected car technology and how it will play a leading role in automotive safety in the future.   

According to Adroit Market Research, “The global connected cars market was valued at $73.18 Billion USD in 2018. The global connected cars market is primarily driven by high adoption in the telematics segment. Along with that, factors that have reinforced the market include trend of connectivity solutions and an increase in the need for safety & security.”

Siyata Mobile Inc. (TSX-V:SIM) (OTCQX:SYATF), a leading provider of in-vehicle communication devices is evolving the conversation surrounding automotive safety having just announced the launch of its groundbreaking Uniden ® UV350 on the AT&T network and FirstNet platform.

Read this in full at https://www.investorideas.com/news/2019/auto/06051Stocks-VehicleSafety.asp

FirstNet is being built with AT&T in a public-private partnership with the First Responder Network Authority (FirstNet Authority) – an independent agency within the federal government. It’s designed for first responders and those critical to their emergency response. With this much-needed technology upgrade, first responders can connect to the critical information they need every day and in every emergency.

The FirstNet Ready UV350 device supports FirstNet’s First Priority – which includes priority and preemption for first responders – and FirstNet’s Band 14 spectrum. The company’s UV350 is the only device specifically designated for in-vehicle communications that has been tested and certified to operate on FirstNet.

The Uniden® UV350 is built and designed to minimize the excessive clutter often found in the cabin of firetrucks, ambulances, yellow school buses and police squad cars by combining the functions of multiple devices into one. Using Push-to-Talk Over Cellular (PoC), drivers can communicate crystal-clear sound at the touch of a button, and unlike traditional cellular communication devices, the UV350 is powered by the vehicle battery, ensuring drivers are always connected in emergency situations.

Before being certified and approved for use on FirstNet, devices are subject to hundreds of tests that cover a number of aspects, from security and durability to network impacts. This helps make sure that they can meet the needs of first responders. All FirstNet Ready devices are listed at on the FirstNet device page.

“FirstNet devices and modules go through extensive review, so First Responders can be confident that Siyata’s UV350 meets the highest standards for reliability, security and performance,” said Bob Sloan, Chief Operating Officer, FirstNet program at AT&T. “The more tools public safety has access to on their network, the more we can help them achieve their mission. We are happy to be the first U.S. cellular carrier to launch Uniden’s NextGen Vehicle Communicator – an innovative in-vehicle mounted phablet. We believe it will be an excellent answer for both existing and newly migrating FirstNet subscribers seeking an in-vehicle communication device.”

A recent Frost and Sullivan report supports the Siyata Mobile Inc. strategy noting, "Connected car makers will be eager to build strategic partnerships with telecom providers and communication module makers to augment on-road safety and offer in-vehicle, data-rich services."

BlackBerry Limited (NYSE:BB) (TSX: BB), looking at connected cars and security says, “Cybersecurity is top of mind for automakers as their cars become more connected to the outside world. Today’s vehicles are computers on wheels—with over 100 million lines of software per car. This degree of connectivity allows bad actors to hack into cars and their software, with the potential to create havoc. The risk posed to automakers can be mitigated with a well-designed end-to-end security solution and alignment with security best practices.”

BlackBerry received $40 million in federal funding to help develop technologies that make cars safer, more connected to cyberspace and eventually, capable of driving themselves. Back in February the company announced that it had completed an Australian Information Security Registered Assessors Program (IRAP) assessment by an accredited IRAP auditor.  The assessment enables BlackBerry Cylance to obtain the IRAP certification. The company will be the first endpoint security provider to receive IRAP certification, allowing Australian government agencies to protect their environments with AI-driven security solutions.

Solutions certified under the IRAP program meet the expected Australian government security requirements, as defined by the attorney general's Protective Security Policy Framework (PSPF) and the Australian Government Information Security Manual (ISM). All federal government entities applying the ISM are restricted to using IRAP-compliant applications running on cloud services listed on the Certified Cloud Services List. 

"Federal agencies can now take advantage of AI-driven, prevention-first security solutions for the first time. With access to BlackBerry Cylance solutions, government and commercial entities can drive a prevention-first strategic approach to cyber, without the friction and complexity that occurs with many other security controls today," said Jason Duerden, country manager for Australia and New Zealand at BlackBerry Cylance. "With this assessment and certification, BlackBerry Cylance is now in a position to proactively secure Australia's most important federal assets, offer the outcome of a safer Australia in which to live and do business, and in turn further our mission to protect every endpoint under the sun."

U.S. electric car maker Tesla Inc. (NASDAQ: TSLA), predicted in 2016 to become the ultimate ‘Connected Car, set the benchmark for what the connected car could be with the launch of the Model S.

According to a report from  CNBC in early May this year, citing a Citibank and Goldman Sachs hosted  “broad investor call” with Tesla executives, “Musk confidently told investors  that autonomous driving will transform Tesla into a company with a $500 billion market cap. Its current market cap stands around $42 billion. He also said that existing Tesla’s will increase in value as self-driving capabilities are added via software, and will be worth up to $250,000 within three years.”

Continued: “He (Musk) said that even though Tesla drivers need to keep hands on the wheel today, that will become less necessary over time. Musk said that competitors such as GM’s Cruise and Alphabet’s Waymo can’t catch up because Tesla has a fleet of connected cars on the road today, and a proprietary chip.”

Mobility technology company, Magna International Inc. (TSX: MG), can lay claim to an industry first in connected car technology applications. In 2017, Magna, 3M and the Michigan Department of Transportation started testing vehicle-to-infrastructure connectivity in real-world situations, such as highway work zones and county roads.

According to Magna, the collaboration began with the launch of the nation’s first vehicle-to-infrastructure connected work zone, which was built along a three-mile section of I-75 in Oakland County, Michigan.

“The ability for vehicles to communicate with other vehicles and the infrastructure ‘shows great promise in helping to avoid crashes, ease traffic and improve the environment’, says the US Department of Transportation.”

At CES earlier this year, Bosch and Mojio, the leading platform for connected cars, announced a jointly developed, IoT integrated emergency response solution. The new offering adds crash detection and emergency call (eCall) response to an existing connected car solution from Mojio. Through the simple combination of a plug-and-play device for the vehicle’s OBD-II port and a mobile app, nearly a million consumers in North America and Europe have already upgraded their cars with Mojio’s white-label connected car solutions. These connected car offerings are deployed by Mojio’s portfolio of mobile network operator customers, including Deutsche Telekom, T-Mobile US and Telus (TSX: T) (NYSE: TU).

Telus is pushing its Connected Car Drive + technology saying, “From a few vehicles to a full scale fleet, the TELUS Connected Vehicle portfolio empowers business owners to efficiently & safely manage their vehicles. “

“With more than a billion unconnected cars still on the road today, industry collaboration is critical to accelerate the deployment of connected mobility services across the globe,” said Kenny Hawk, CEO, Mojio. “Together with Bosch, we’re addressing the key barriers that automakers face in building profitable connected mobility services - in turn, helping OEMs shift their focus towards the rapidly-evolving expectations of the global driving community.”

‘With more than a billion unconnected cars still on the road today’, this clearly shows the massive potential future of this industry, and analysts say that Connected Car tech is the most significant trend in the automotive sector in the last 50 years.  

About Investorideas.com - News that Inspires Big Investing Ideas

https://www.investorideas.com/About/

Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends  from Investorideas.com with our news alerts, articles, podcasts and videos talking about cannabis, crypto, technology including AI and IoT, mining, sports biotech, water, renewable energy and more. Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI. 

Disclaimer/Disclosure: Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: this news article featuring Siyata Mobile Inc. (TSX-V:SIM) (OTCQX: SYATF) is a paid for article on Investorideas.com .  More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Contact management and IR of each company directly regarding specific questions.

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Follow us on Social Media

https://www.facebook.com/Investorideaspotcasts/

https://twitter.com/MJInvestorIdeas

https://www.instagram.com/potcasts_investorideas/

Contact Investorideas.com

800-665-0411